Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
12 juil. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
Hematopoietic Stem Cells Transplantation Market revenue to cross USD 3.12 Billion by 2035, says Research Nester
10 juil. 2023 07h30 HE
|
Research Nester
New York, July 10, 2023 (GLOBE NEWSWIRE) -- The global hematopoietic stem cells transplantation market is estimated to grow at a CAGR of ~10% from 2023 to 2035. The market is estimated to garner a...
Monthly information on share capital and company voting rights
05 juil. 2023 16h30 HE
|
Cellectis Inc.
PARIS, July 05, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting...
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
28 juin 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...
Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
23 juin 2023 05h00 HE
|
First Light Acquisition Group; Caldi Biotherapeutics
SAN DIEGO, June 23, 2023 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of...
Tessa Therapeutics’ ‘Off-the-Shelf’ CAR-T Therapy Shows Promising Results in Early-Stage Study of Hodgkin Lymphoma
15 juin 2023 21h19 HE
|
Tessa Therapeutics Ltd
78% Overall Response Rate (14/18 patients), including seven patients exhibiting a complete response to TT11X allogeneic CAR-T therapySafety data encouraging with no graft-versus-host-disease and no...
Monthly information on share capital and company voting rights
13 juin 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
09 juin 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
05 juin 2023 16h30 HE
|
Cellectis Inc.
Preclinical data on UCART20x22, Cellectis’ first allogeneic dual CAR T-cell product candidate to treat B-NHL, presented at an oral session Encouraging data presented on gene editing process using...
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
31 mai 2023 16h50 HE
|
Cellectis Inc.
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...